Larvol Delta - Cebranopadol-a-novel-firstinclass-analgesic-drug-candidate-first-experience-with-cancerrelated-pain-for-up-to-26-weeks

cebranopadol (GRT6005) - Assertio, Grunenthal

http://www.ncbi.nlm.nih.gov/pubmed/31152783

Jun 4, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next